Literature DB >> 27849402

A Review of the Role of Intravitreal Corticosteroids as an Adjuvant to Antibiotics in Infectious Endophthalmitis.

Dawn Ching Wen Ho1, Aniruddha Agarwal2,3, Cecilia S Lee4, Jay Chhablani5, Vishali Gupta3, Manoj Khatri6, Jayabalan Nirmal7, Carlos Pavesio8, Rupesh Agrawal1,7,8,9.   

Abstract

Infectious endophthalmitis is an important cause of vision loss worldwide. This entity most often occurs as a complication of intraocular surgery especially following cataract surgery or intravitreal injection. Endophthalmitis is regarded as a serious complication following ocular surgery and the final visual outcome is fundamentally contingent on timely recognition and intervention. Intravitreal and oral antibiotics in combination with pars plana vitrectomy or vitreous aspiration remain the mainstay in the management of endophthalmitis. However, significant inflammation may persist even after sterilization of the intraocular cavities with appropriate antibiotics resulting in failure of treatment. This forms the basis for the use of intravitreal corticosteroids as an adjuvant to antibiotics in the management of infectious endophthalmitis. In the index manuscript, we review the existing literature to determine the role of intravitreal corticosteroids as an adjuvant to antibiotics in treating infectious endophthalmitis, and discuss their beneficial effects and controversial concerns.

Entities:  

Keywords:  Antibiotics; antifungals; corticosteroids; endophthalmitis; intravitreal steroids; intravitreal therapy; uveitis

Mesh:

Substances:

Year:  2016        PMID: 27849402      PMCID: PMC5557691          DOI: 10.1080/09273948.2016.1245758

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  44 in total

1.  Timing of dexamethasone treatment in experimental Staphylococcus aureus endophthalmitis.

Authors:  M O Yoshizumi; G C Lee; R A Equi; I T Kim; H Pitchekian-Halabi; S A Adamu; B J Mondino
Journal:  Retina       Date:  1998       Impact factor: 4.256

2.  Failure of intravitreal dexamethasone to diminish inflammation or retinal toxicity in an experimental model of Bacillus cereus endophthalmitis.

Authors:  John S Pollack; Douglas J Beecher; Jose S Pulido; Amy C Lee Wong
Journal:  Curr Eye Res       Date:  2004 Oct-Nov       Impact factor: 2.424

Review 3.  Evidence for and against intravitreous corticosteroids in addition to intravitreous antibiotics for acute endophthalmitis.

Authors:  Diem K Bui; Petros E Carvounis
Journal:  Int Ophthalmol Clin       Date:  2014

4.  Role of intravitreal triamcinolone acetonide in the treatment of postoperative endophthalmitis.

Authors:  Naomi S Falk; Paul M Beer; George B Peters
Journal:  Retina       Date:  2006 May-Jun       Impact factor: 4.256

5.  Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis.

Authors:  R O Graham; G A Peyman
Journal:  Arch Ophthalmol       Date:  1974-08

Review 6.  On the retinal toxicity of intraocular glucocorticoids.

Authors:  Alicia Torriglia; Fatemeh Valamanesh; Francine Behar-Cohen
Journal:  Biochem Pharmacol       Date:  2010-07-21       Impact factor: 5.858

7.  Acute endophthalmitis following intravitreal triamcinolone acetonide injection.

Authors:  Darius M Moshfeghi; Peter K Kaiser; Ingrid U Scott; Jonathan E Sears; Matthew Benz; Juan P Sinesterra; Richard S Kaiser; Sophie J Bakri; Raj K Maturi; Jonathan Belmont; Paul M Beer; Timothy G Murray; Hugo Quiroz-Mercado; William F Mieler
Journal:  Am J Ophthalmol       Date:  2003-11       Impact factor: 5.258

8.  Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection.

Authors:  H W Kwak; D J D'Amico
Journal:  Arch Ophthalmol       Date:  1992-02

9.  Suppression of phagocytosis by dexamethasone in macrophage cultures: inability of arachidonic acid, indomethacin, and nordihydroguaiaretic acid to reverse the inhibitory response mediated by a steroid-inducible factor.

Authors:  J Becker; R J Grasso
Journal:  Int J Immunopharmacol       Date:  1985

10.  Incidence and Determinants of Endophthalmitis within 6 Months of Surgeries over a 2-Year Period at King Khaled Eye Specialist Hospital, Saudi Arabia: A Review.

Authors:  Rajiv Khandekar; Saeed Al-Motowa; Hind M Alkatan; Mohammed Karaoui; Anne Ortiz
Journal:  Middle East Afr J Ophthalmol       Date:  2015 Apr-Jun
View more
  5 in total

1.  Effectiveness of immediate vitrectomy and intravitreal antibiotics for post-injection endophthalmitis.

Authors:  Kai Januschowski; Karl Thomas Boden; Peter Szurman; Peter Stalmans; Rudolf Siegel; Núria Pérez Guerra; Sören Leif Becker; Annekatrin Rickmann; Lukas Bisorca-Gassendorf
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-01-27       Impact factor: 3.117

2.  Innate Immune Interference Attenuates Inflammation In Bacillus Endophthalmitis.

Authors:  Md Huzzatul Mursalin; Phillip S Coburn; Frederick C Miller; Erin T Livingston; Roger Astley; Michelle C Callegan
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-11-02       Impact factor: 4.799

3.  Retinal Detachment After Endophthalmitis: Risk Factors and Outcomes.

Authors:  Tiantian Wang; Omar Moinuddin; Rebhi Abuzaitoun; Min Hwang; Cagri Besirli; Thomas J Wubben; David N Zacks
Journal:  Clin Ophthalmol       Date:  2021-04-13

Review 4.  Aspergillus Endophthalmitis: Epidemiology, Pathobiology, and Current Treatments.

Authors:  Alisha Khambati; Robert Emery Wright; Susmita Das; Shirisha Pasula; Alejandro Sepulveda; Francis Hernandez; Mamta Kanwar; Pranatharthi Chandrasekar; Ashok Kumar
Journal:  J Fungi (Basel)       Date:  2022-06-22

Review 5.  The Diagnosis and Treatment of Fungal Endophthalmitis: An Update.

Authors:  Ciprian Danielescu; Horia Tudor Stanca; Raluca-Eugenia Iorga; Diana-Maria Darabus; Vasile Potop
Journal:  Diagnostics (Basel)       Date:  2022-03-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.